Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Nucleic acid ligand binding site identification|
|Abstract:||This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.|
|Inventor(s):||Gold; Larry (Boulder, CO), Tuerk; Craig (Morehead, KY)|
|Assignee:||Gilead Sciences, Inc. (Foster City, CA)|
|Filing Date:||Oct 18, 2001|
|Claims:||1. A method for identifying a nucleic acid binding protein's binding site on a region of a DNA or RNA comprising: a) providing a nucleic acid ligand to the nucleic acid binding protein wherein said ligand has a sequence and a structure selected from the group consisting of loops, stems, hairpins, pseudoknots, helices and bulges; b) adding said nucleic acid ligand to said nucleic acid binding protein and said DNA or RNA region; and c) determining whether said added nucleic acid ligand inhibits said protein from binding to said RNA or DNA region, whereby if the nucleic acid ligand is inhibitory, the sequence or structure of said inhibitory nucleic acid ligand assists in the identification of the binding site in the DNA or RNA region or its structure. |
2. The method of claim 1 wherein said nucleic acid ligand is provided by the method comprising the steps of: a) contacting a candidate mixture of nucleic acids each of which have a randomized sequence with the binding protein, whereby nucleic acids having an increased affinity to the protein relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby a nucleic acid ligand of the protein may be identified.
3. The method of claim 1 wherein the DNA or RNA region contains a site selected from the group consisting of a promoter, an origin of replication, a ribosomal binding site and a tRNA binding site.
4. The method of claim 1 wherein the protein regulates transcription.
5. The method of claim 1 wherein the protein regulates translation.
6. The method of claim 1 wherein the protein is selected from the group consisting of transcriptional activators, transcriptional repressors, transcription complexes at promoter sites, replication accessory proteins, DNA polymerases, RNA polymerases and translational repressors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.